Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Corcept Therapeutics
(NQ:
CORT
)
45.43
+0.18 (+0.40%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Corcept Therapeutics
< Previous
1
2
3
4
5
6
7
Next >
These 3 Stocks Are Winning the Bear Market -- Here's How
October 21, 2022
Picking the right markets to compete in makes surviving bear markets much more manageable for these companies.
Via
The Motley Fool
7 Under-the-Radar Stocks With 100% Upside Potential
October 17, 2022
If you're looking for under-the-radar stocks in the current market environment, you're likely to find many imposters so tread carefully.
Via
InvestorPlace
Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)
October 11, 2022
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Corcept Therapeutics Return On Capital Employed Overview
August 11, 2022
Via
Benzinga
Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings
July 26, 2022
IBD 50 member Amphastar Pharmaceuticals stock is expected to report on Aug. 9 and is trading approximately 12% below a 42.41 entry.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022
August 01, 2022
Upgrades
Via
Benzinga
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
July 15, 2022
The group has several commonalities, including strong ratings and promising charts.
Via
Investor's Business Daily
3 Biotech Stocks Outperforming a Bear Market
July 15, 2022
These biotech stocks are the most attractive from a valuation and growth perspective as they are less impacted by a slowing economy or change in monetary policy.
Via
InvestorPlace
Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
July 13, 2022
ApellisPharmaceuticals sees its Relative Strength Rating reach the elite 90-plus level.
Via
Investor's Business Daily
Vir Biotechnology Stock Joins Rank Of Stocks With RS Ratings Over 90
July 11, 2022
On Monday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 91 Monday, up from 85 a day earlier.
Via
Investor's Business Daily
Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8%
July 11, 2022
Among its other key ratings, Amsterdam-based gene therapy company Uniqure stock also has a 92 Composite Rating.
Via
Investor's Business Daily
Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating
July 08, 2022
The Relative Strength (RS) Rating for Kezar Life Sciences stock jumped into a new percentile Friday, with a rise from 78 to 81.
Via
Investor's Business Daily
Apellis Pharmaceuticals Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
July 08, 2022
Apellis Pharmaceuticals stock saw its Relative Strength (RS) Rating upgraded to 85 Friday, up from 79 a day earlier.
Via
Investor's Business Daily
Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91
July 05, 2022
Global Blood Therapeutic stock saw a positive improvement to its Relative Strength Rating on Tuesday, rising from 85 to 91.
Via
Investor's Business Daily
Kura Oncology Stock Scores Rising Relative Strength
June 30, 2022
On Thursday, Kura Oncology stock had its Relative Strength (RS) Rating stock upgraded to 93 from 81 a day earlier.
Via
Investor's Business Daily
Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92
June 30, 2022
Syndax Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 80 to 92.
Via
Investor's Business Daily
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
June 30, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Corcept Therapeutics Commences Late-Stage Ovarian Cancer Study
June 29, 2022
Corcept Therapeutics (NASDAQ: CORT) has initiated pivotal Phase 3 clinical trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.
Via
Benzinga
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
June 28, 2022
Amylyx Pharmaceuticals stock reached an key technical benchmark, with its Relative Strength Rating climbing to 95, up from 70 the day before.
Via
Investor's Business Daily
Why Corcept's Pill — And Stock — Is Getting Renewed Attention After Abortion Ruling
June 28, 2022
Corcept makes a Cushing's drug that, by another name, causes medical abortion.
Via
Investor's Business Daily
Corcept Stock Near Buy Point; Strength Rating Jumps To 91
June 23, 2022
The new 91 RS Rating means that Corcept stock has outperformed 90% of all other stocks over the past year.
Via
Investor's Business Daily
Top Mid-Cap Stocks: Trading Opportunities For Next Week - Sunday, June 19
June 19, 2022
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some mid-cap stock opportunities by analyzing...
Via
Talk Markets
Corcept Update
May 18, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
NASDAQ:CORT Investor Alert: Investigation over Potential Wrongdoing at Corcept Therapeutics Incorporated
May 09, 2022
San Diego, CA -- (SBWIRE) -- 05/09/2022 -- Certain directors of Corcept Therapeutics Incorporated are under investigation over potential breaches of fiduciary duties.
Via
SBWire
Preview: Corcept Therapeutics's Earnings
May 04, 2022
Corcept Therapeutics (NASDAQ:CORT) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Corcept Shareholder Notice
April 20, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shareholder Alert: Update on Lawsuit Against Corcept Therapeutics
March 22, 2022
San Diego, CA -- (SBWIRE) -- 03/22/2022 -- The Shareholders Foundation announced an update in the lawsuit that is pending for certain investors in Corcept Therapeutics Incorporated (NASDAQ:CORT)...
Via
SBWire
Corcept Therapeutics's Return On Capital Employed Overview
February 16, 2022
According to Benzinga Pro, during Q4, Corcept Therapeutics (NASDAQ:CORT) earned $32.05 million, a 5.19% increase from the preceding quarter. Corcept Therapeutics also posted a total of $98.82 million...
Via
Benzinga
Recap: Corcept Therapeutics Q4 Earnings
February 15, 2022
Corcept Therapeutics (NASDAQ:CORT) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
February 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.